◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › P › PTCT

PTC Therapeutics Inc (PTCT) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-15

PTC Therapeutics Inc (PTCT) operates in the BIOTECHNOLOGY industry and is headquartered in Warren, United States with about 991 employees. Its market capitalization is roughly $5 billion. In the fiscal year ended 2025-12-31, PTCT reported $1.7B in revenue and $683M in net income.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.

Interactive charts & full statements → Open the PTCT valuation workbench →

PTCT Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2005-12-31	2004-12-31
Total Revenue	$1.0B	$1.7B	$807M	$938M	$699M	$539M	$381M	$307M	$265M	$194M	$83M	$37M	$23M	$31M	$29M	$99M	$5M	$2M
Gross Profit	$829M	$1.7B	$749M	$872M	$654M	$506M	$362M	$295M	$252M	$190M	$83M	$37M	($57M)	($24M)	$34M	$99M	—	—
Gross Margin %	82.1%	95.9%	92.9%	93.0%	93.6%	94.0%	95.0%	96.0%	95.2%	97.7%	100.0%	100.0%	-247.7%	-75.2%	118.0%	100.0%	—	—
Operating Income (EBIT)	$116M	$857M	($303M)	($440M)	($447M)	($374M)	($432M)	($241M)	($116M)	($64M)	($132M)	($167M)	($99M)	($45M)	($27M)	$31M	—	—
Operating Margin %	11.5%	49.5%	-37.5%	-46.9%	-64.0%	-69.5%	-113.4%	-78.6%	-43.7%	-33.1%	-159.7%	-454.6%	-432.9%	-144.9%	-93.2%	30.9%	—	—
Net Income	($39M)	$683M	($363M)	($627M)	($559M)	($524M)	($438M)	($252M)	($128M)	($79M)	($142M)	($170M)	($94M)	($52M)	($26M)	$31M	—	—
Net Margin %	-3.9%	39.4%	-45.0%	-66.8%	-80.0%	-97.3%	-115.1%	-82.0%	-48.4%	-40.6%	-171.8%	-463.6%	-408.3%	-164.6%	-91.2%	31.2%	—	—
EBITDA	$174M	$888M	($120M)	($330M)	($368M)	($368M)	($303M)	($195M)	($89M)	($47M)	($129M)	($164M)	($97M)	($43M)	($24M)	$33M	—	—
Earnings Per Share (EPS)	$-0.61	$7.73	$-4.73	$-8.37	$-7.79	$-7.43	$-6.64	$-4.27	$-2.75	$-2.02	$-4.17	$-5.07	$-2.97	$-4.02	$-1.11	$1.31	—	—
Shares Outstanding (M)	92M	88M	77M	75M	72M	70M	66M	59M	47M	39M	34M	34M	32M	13M	24M	24M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PTCT Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$361M	$273M	$165M	$211M	$179M	$1.2B	$213M	$197M
Gross Profit	$341M	$245M	$148M	$95M	$167M	$1.2B	$197M	$186M
Gross Margin %	94.5%	89.7%	90.1%	45.1%	93.6%	98.9%	92.4%	94.5%
Operating Income (EBIT)	$149M	$46M	($82M)	$3M	($35M)	$970M	($162M)	($55M)
Operating Margin %	41.3%	16.8%	-49.6%	1.4%	-19.5%	82.5%	-76.2%	-27.7%
Net Income	$83M	($3M)	($135M)	$16M	($65M)	$867M	($66M)	($107M)
Net Margin %	23.2%	-1.0%	-82.0%	7.5%	-36.2%	73.7%	-30.9%	-54.2%
EBITDA	$162M	$62M	($71M)	$21M	($33M)	$971M	($47M)	($50M)
Earnings Per Share (EPS)	$0.91	$-0.03	$-1.67	$0.18	$-0.83	$10.03	$-0.85	$-1.39
Shares Outstanding (M)	92M	83M	81M	87M	78M	86M	77M	77M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PTCT Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2005-12-31	2004-12-31
Cash from Operations (CFO)	($30M)	$711M	($108M)	($158M)	($357M)	($251M)	($194M)	($99M)	($28M)	($10M)	($104M)	($124M)	($57M)	($47M)	($48M)	($21M)	—	—
Capital Expenditures (CapEx)	$301M	$300M	$74M	$121M	$152M	$85M	$56M	$45M	$16M	$3M	$2M	$3M	$5M	$1M	$0M	$0M	$1M	$1M
Free Cash Flow (FCF)	($333M)	$411M	($182M)	($279M)	($509M)	($337M)	($250M)	($144M)	($43M)	($13M)	($105M)	($127M)	($62M)	($48M)	($48M)	($21M)	—	—
FCF Margin %	-33.0%	23.8%	-22.6%	-29.8%	-72.9%	-62.5%	-65.7%	-46.9%	-16.3%	-6.8%	-127.4%	-345.6%	-269.7%	-152.5%	-167.2%	-21.1%	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PTCT Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$129M	($59M)	($34M)	($66M)	($58M)	$870M	($30M)	($77M)
Capital Expenditures (CapEx)	$7M	$1M	$37M	$256M	$4M	$3M	$6M	$11M
Free Cash Flow (FCF)	$122M	($60M)	($72M)	($323M)	($62M)	$868M	($37M)	($88M)
FCF Margin %	33.8%	-22.2%	-43.5%	-152.9%	-34.8%	73.8%	-17.1%	-44.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PTCT Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2005-12-31	2004-12-31
Total Assets	$3.2B	$2.9B	$1.7B	$1.9B	$1.7B	$1.9B	$2.2B	$1.6B	$1.1B	$392M	$269M	$368M	$333M	$152M	$13M	$44M	$44M	$39M
Cash & Cash Equivalents	$1.1B	$985M	$780M	$594M	$280M	$773M	$209M	$288M	$228M	$191M	$232M	$339M	$315M	$15M	$3M	$28M	$11M	$7M
Total Liabilities	$3.4B	$3.1B	$2.8B	$2.7B	$2.1B	$1.9B	$1.7B	$1.0B	$768M	$235M	$150M	$70M	$35M	$15M	$32M	$283M	$6M	$4M
Total Debt (Short + Long-Term)	$609M	$2.6B	$2.4B	$2.1B	$656M	$442M	$318M	$319M	$153M	$206M	$139M	$186M	$0M	$0M	$5M	$12M	$1M	$0M
Total Shareholders' Equity	($165M)	($205M)	($1.1B)	($819M)	($347M)	$1M	$482M	$594M	$351M	$156M	$120M	$298M	$298M	$137M	($19M)	($239M)	$38M	$35M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PTCT viewer.

Other Companies in BIOTECHNOLOGY

SRRK · Scholar Rock Holding Corp — $6 billion
LGND · Ligand Pharmaceuticals Incorporated — $6 billion
CRSP · Crispr Therapeutics AG — $5 billion
COGT · Cogent Biosciences Inc — $5 billion
DNTH · Dianthus Therapeutics Inc. — $5 billion
DFTX · Definium Therapeutics, Inc. — $5 billion
ERAS · Erasca Inc — $5 billion
PBLS · Parabilis Medicines, Inc. Common Stock — $5 billion

← PTCIL All “P” companies PTEC →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.